Peptide Association
Start Your Consultation
All peptides
OncologyFDA Approved

Leuprolide (Lupron) - Oncology

Intramuscular injection (depot), Subcutaneous injection
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

A GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in premenopausal breast cancer. Chronic administration produces sustained downregulation of pituitary GnRH receptors, achieving medical castration with testosterone levels below 50 ng/dL.

Mechanism of Action

The initial testosterone flare can be mitigated by co-administration of an antiandrogen. Depot formulations provide sustained release for up to 6 months.

Research Summary & Key Findings

Cornerstone of prostate cancer treatment since the 1980s, replacing surgical orchiectomy as the primary method of androgen deprivation. Combined with radiation therapy in locally advanced prostate cancer based on RTOG trials showing overall survival benefit. ADT with leuprolide associated with metabolic side effects including insulin resistance, dyslipidemia, and osteoporosis requiring monitoring.

Clinical Status

FDA Approved

Leuprolide (Lupron) - Oncology has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intramuscular injection (depot)Subcutaneous injection

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Oncology

Carfilzomib (Kyprolis)

FDA Approved

A tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...

View details

Bortezomib (Velcade)

FDA Approved

A modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...

View details

Lutetium-177 dotatate (Lutathera)

FDA Approved

A radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...

View details

Degarelix (Firmagon)

FDA Approved

Degarelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of ...

View details

Start Your Consultation

Get an AI-proposed Leuprolide (Lupron) - Oncology protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Leuprolide (Lupron) - Oncology.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.